BR9609782A - Inibidores de adesão culular - Google Patents

Inibidores de adesão culular

Info

Publication number: BR9609782A
Authority: BR; Brazil
Prior art keywords: culinary; adhesion inhibitors; inhibitors; adhesion; culinary adhesion
Prior art date: 1995-07-11

Application number

BR9609782A

Other languages

English (en)

Inventor

Ronald A Almquist

Steven P Adams

Ko-Chung Lin

Mary Beth Carter

Wen-Cherng Lee

Craig N Zimmermann

Alfredo C Castro

Charles E Hammond

Julio Herman Cuervo

Carol Lee Ensinger

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-11

Filing date

1996-07-11

Publication date

1999-03-09

1996-07-11 Application filed by Biogen Inc filed Critical Biogen Inc

1999-03-09 Publication of BR9609782A publication Critical patent/BR9609782A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Crystallography & Structural Chemistry (AREA)
Pulmonology (AREA)
Zoology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)

BR9609782A 1995-07-11 1996-07-11 Inibidores de adesão culular BR9609782A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/498,237 US6248713B1 (en)	1995-07-11	1995-07-11	Cell adhesion inhibitors
PCT/US1996/011570 WO1997003094A1 (en)	1995-07-11	1996-07-11	Cell adhesion inhibitors

Publications (1)

Publication Number	Publication Date
BR9609782A true BR9609782A (pt)	1999-03-09

Family

ID=23980177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9609782A BR9609782A (pt)	1995-07-11	1996-07-11	Inibidores de adesão culular

Country Status (27)

Country	Link
US (2)	US6248713B1 (pt)
EP (1)	EP0842196B1 (pt)
JP (2)	JPH11511124A (pt)
KR (1)	KR100531586B1 (pt)
CN (1)	CN1195778C (pt)
AU (1)	AU716276B2 (pt)
BG (1)	BG63876B1 (pt)
BR (1)	BR9609782A (pt)
CA (1)	CA2226868A1 (pt)
CZ (1)	CZ299054B6 (pt)
DE (1)	DE69637328T2 (pt)
EA (2)	EA001594B1 (pt)
EE (2)	EE03694B1 (pt)
FI (1)	FI980033A7 (pt)
HU (1)	HUP9802202A3 (pt)
IL (1)	IL122783A (pt)
IS (1)	IS4648A (pt)
MX (1)	MX9800348A (pt)
NO (1)	NO980097L (pt)
NZ (1)	NZ312950A (pt)
PL (1)	PL188446B1 (pt)
RO (1)	RO121032B1 (pt)
SK (1)	SK3798A3 (pt)
TR (1)	TR199800028T1 (pt)
TW (1)	TW570927B (pt)
UA (1)	UA71888C2 (pt)
WO (1)	WO1997003094A1 (pt)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6248713B1 (en) *	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
US6037324A (en)	1996-01-04	2000-03-14	Leukosite, Inc.	Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
CA2261974A1 (en)	1996-07-25	1998-02-05	Biogen, Inc.	Molecular model for vla-4 inhibitors
US6686350B1 (en)	1996-07-25	2004-02-03	Biogen, Inc.	Cell adhesion inhibitors
US6291511B1 (en)	1997-05-29	2001-09-18	Merck & Co., Inc.	Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en)	1997-05-29	2001-04-24	Merck & Co., Inc.	Sulfonamides as cell adhesion inhibitors
WO1998053817A1 (en) *	1997-05-29	1998-12-03	Merck & Co., Inc.	Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en)	1997-05-29	2005-06-07	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (en) *	1997-05-30	1998-12-03	Celltech Therapeutics Limited	Anti-inflammatory tyrosine derivatives
US6583139B1 (en)	1997-07-31	2003-06-24	Eugene D. Thorsett	Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en)	1997-07-31	2001-09-18	Athena Neurosciences, Inc.	4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
AR016133A1 (es) *	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6559127B1 (en)	1997-07-31	2003-05-06	Athena Neurosciences, Inc.	Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en)	1997-07-31	2002-12-10	Athena Neurosciences, Inc.	Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en)	1997-07-31	2002-12-03	Eugene D. Thorsett	Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en)	1997-07-31	2006-04-18	Elan Pharmaceuticals, Inc.	Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en)	1997-07-31	2002-07-23	Athena Neurosciences, Inc.	Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en)	1997-07-31	2005-09-06	Elan Pharmaceuticals, Inc.	Anti-inflammatory compositions and method
US6362341B1 (en)	1997-07-31	2002-03-26	Athena Neurosciences, Inc.	Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de)	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) *	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6069163A (en) *	1997-10-21	2000-05-30	Merck & Co., Inc.	Azapeptide acids as cell adhesion inhibitors
BR9813331A (pt) *	1997-10-31	2000-08-22	Aventis Pharma Ltd	Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina
GB9723789D0 (en)	1997-11-12	1998-01-07	Zeneca Ltd	Chemical compounds
US6020347A (en) *	1997-11-18	2000-02-01	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
WO1999025685A1 (en) *	1997-11-18	1999-05-27	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
DE19751251A1 (de)	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6191171B1 (en)	1997-11-20	2001-02-20	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
US6090841A (en) *	1997-11-21	2000-07-18	Merck & Co., Inc.	Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en)	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
AU751950B2 (en) *	1997-11-24	2002-09-05	Merck & Co., Inc.	Substituted beta-alanine derivatives as cell adhesion inhibitors
US6407065B1 (en)	1998-01-23	2002-06-18	Novartis Ag	VLA-4 antagonists
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
GB9805655D0 (en)	1998-03-16	1998-05-13	Celltech Therapeutics Ltd	Chemical compounds
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
AU3716499A (en) *	1998-04-21	1999-11-08	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en)	1998-05-22	1998-07-22	Celltech Therapeutics Ltd	Chemical compounds
EA002988B1 (ru)	1998-05-28	2002-12-26	Байоджен, Инк.	(r)-n-[[4-[[(2-метилфениламино)карбонил]амино]фенил]ацетил]-l-пропил-3- метил- бета-аланин и его применение в качестве ингибитора клеточной адгезии, опосредуемой интегрином альфа4бета1
GB9811969D0 (en)	1998-06-03	1998-07-29	Celltech Therapeutics Ltd	Chemical compounds
GB9814414D0 (en)	1998-07-03	1998-09-02	Celltech Therapeutics Ltd	Chemical compounds
AU1915399A (en) *	1998-07-10	2000-02-01	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
GB9916374D0 (en)	1998-07-23	1999-09-15	Zeneca Ltd	Chemical compounds
GB9821061D0 (en)	1998-09-28	1998-11-18	Celltech Therapeutics Ltd	Chemical compounds
GB9821222D0 (en)	1998-09-30	1998-11-25	Celltech Therapeutics Ltd	Chemical compounds
GB9825652D0 (en)	1998-11-23	1999-01-13	Celltech Therapeutics Ltd	Chemical compounds
GB9826174D0 (en)	1998-11-30	1999-01-20	Celltech Therapeutics Ltd	Chemical compounds
GB9828074D0 (en) *	1998-12-18	1999-02-17	Glaxo Group Ltd	Therapeutically useful compounds
ES2297943T3 (es) *	1998-12-23	2008-05-01	Aventis Pharma Limited	Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
US6407066B1 (en)	1999-01-26	2002-06-18	Elan Pharmaceuticals, Inc.	Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19922462A1 (de)	1999-05-17	2000-11-23	Aventis Pharma Gmbh	Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6518283B1 (en)	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
RU2264386C2 (ru) *	1999-06-30	2005-11-20	Дайити Фармасьютикал Ко., Лтд.	Соединения ингибиторы vla-4
CA2369308A1 (en) *	1999-06-30	2001-01-04	Daiichi Pharmaceutical Co., Ltd.	Vla-4 inhibitor compounds
US6756378B2 (en)	1999-06-30	2004-06-29	Pharmacopeia Drug Discovery, Inc.	VLA-4 inhibitor compounds
PT1265606E (pt)	1999-08-13	2007-01-31	Biogen Idec Inc	Inibidores da adesão celular
US6534513B1 (en)	1999-09-29	2003-03-18	Celltech R&D Limited	Phenylalkanoic acid derivatives
EP2332578A1 (en)	1999-12-16	2011-06-15	Biogen Idec MA Inc.	Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US6455539B2 (en)	1999-12-23	2002-09-24	Celltech R&D Limited	Squaric acid derivates
KR20020067050A (ko)	1999-12-28	2002-08-21	화이자 프로덕츠 인코포레이티드	염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
JP2003531141A (ja)	2000-04-17	2003-10-21	セルテックアールアンドディリミテッド	エナミン誘導体
US6545013B2 (en)	2000-05-30	2003-04-08	Celltech R&D Limited	2,7-naphthyridine derivatives
US6403608B1 (en)	2000-05-30	2002-06-11	Celltech R&D, Ltd.	3-Substituted isoquinolin-1-yl derivatives
WO2002004426A1 (en)	2000-07-07	2002-01-17	Celltech R & D Limited	Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (ja)	2000-08-02	2004-02-19	セルテック　アール　アンド　ディ　リミテッド	３位置換イソキノリン−１−イル誘導体
WO2002040021A2 (en) *	2000-11-17	2002-05-23	Idenix (Cayman) Limited	Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
US6875743B1 (en)	2000-11-28	2005-04-05	Biogen, Inc.	Cell adhesion inhibitors
MXPA03005838A (es)	2000-12-28	2003-09-10	Daichi Pharmaceutical Co Ltd	Inhibidores de antigenos de aparicion muy tardia-4.
DE10111877A1 (de)	2001-03-10	2002-09-12	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB2377933A (en)	2001-07-06	2003-01-29	Bayer Ag	Succinic acid derivatives useful as integrin antagonists
DE10137595A1 (de)	2001-08-01	2003-02-13	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
WO2003016919A1 (en) *	2001-08-20	2003-02-27	Honeywell International Inc.	Micro-machined electromechanical system (mems) accelerometer device having arcuately shaped flexures
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
WO2004041279A1 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Gamma-aminoamide modulators of chemokine receptor activity
WO2005009992A1 (ja)	2003-07-24	2005-02-03	Daiichi Pharmaceutical Co., Ltd.	シクロヘキサンカルボン酸類
CN1301426C (zh) *	2003-08-19	2007-02-21	友达光电股份有限公司	窄边框设计的液晶显示面板及其制作方法
JPWO2005066124A1 (ja) *	2003-12-26	2007-12-20	第一三共株式会社	ピロリジン誘導体の製造法
US7576175B2 (en) *	2004-05-27	2009-08-18	The Regents Of The University Of California	Alpha-4 beta-1 integrin ligands for imaging and therapy
US20060063828A1 (en) *	2004-06-28	2006-03-23	Weingarten M D	1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7196112B2 (en)	2004-07-16	2007-03-27	Biogen Idec Ma Inc.	Cell adhesion inhibitors
US7140250B2 (en) *	2005-02-18	2006-11-28	Honeywell International Inc.	MEMS teeter-totter accelerometer having reduced non-linearty
US8129366B2 (en)	2005-12-13	2012-03-06	Daiichi Sankyo Company, Limited	VLA-4 inhibitory drug
AU2008219007A1 (en)	2007-02-20	2008-08-28	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
ATE502920T1 (de)	2007-12-14	2011-04-15	Pulmagen Therapeutics Asthma Ltd	Indole und ihre therapeutische verwendung
JP5639039B2 (ja)	2008-04-11	2014-12-10	メリマックファーマシューティカルズインコーポレーティッド	ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010031183A1 (en)	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Indole derivatives as crth2 receptor antagonists
CA2748943A1 (en)	2009-02-09	2010-08-12	Supergen, Inc.	Pyrrolopyrimidinyl axl kinase inhibitors
GB0902648D0 (en)	2009-02-17	2009-04-01	Argenta Discovery Ltd	Pharmaceutical compounds and compositions
CN102395586A (zh)	2009-02-17	2012-03-28	奇斯药制品公司	作为p38map激酶抑制剂的三唑并吡啶衍生物
SI2401269T1 (sl)	2009-02-24	2014-04-30	Merck Sharp & Dohme Corp.	Derivati indola kot crth2 receptorski antagonisti
US8362068B2 (en)	2009-12-18	2013-01-29	Idenix Pharmaceuticals, Inc.	5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
GB201009731D0 (en)	2010-06-10	2010-07-21	Pulmagen Therapeutics Inflamma	Kinase inhibitors
WO2012031228A2 (en)	2010-09-02	2012-03-08	The Regents Of The University Of California	Llp2a-bisphosphonate conjugates for osteoporosis treatment
US8927559B2 (en)	2010-10-11	2015-01-06	Merck Sharp & Dohme Corp.	Quinazolinone-type compounds as CRTH2 antagonists
WO2012087861A1 (en)	2010-12-23	2012-06-28	Merck Sharp & Dohme Corp.	Quinoxalines and aza-quinoxalines as crth2 receptor modulators
BR112013028430A2 (pt)	2011-05-04	2017-08-01	Merck Sharp & Dohme	composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
PE20140788A1 (es)	2011-06-17	2014-07-09	Merck Sharp & Dohme	Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2
US8987456B2 (en)	2011-10-05	2015-03-24	Merck Sharp & Dohme Corp.	3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
PE20141370A1 (es)	2011-12-09	2014-10-17	Chiesi Farma Spa	Inhibidores de quinasa
RU2586333C1 (ru)	2011-12-09	2016-06-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта
MY167216A (en)	2011-12-09	2018-08-14	Chiesi Farm Spa	Kinase inhibitors
WO2014195402A1 (en)	2013-06-06	2014-12-11	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
CN104817622A (zh) *	2014-01-30	2015-08-05	陈光健	寡肽cd04及其制备方法和应用
CN104817615A (zh) *	2014-01-30	2015-08-05	陈光健	寡肽cd05及其制备方法和应用
CN104817625A (zh) *	2014-01-30	2015-08-05	陈光健	寡肽cd03及其制备方法和应用
CN104817613A (zh) *	2014-01-30	2015-08-05	陈光健	寡肽cd06及其制备方法和应用
CN105294830A (zh) *	2014-06-18	2016-02-03	陈光健	一种二肽分子及其制备方法和应用
MX391259B (es)	2015-10-14	2025-03-21	X Therma Inc	Composiciones y métodos para reducir la formación de cristales de hielo.
TW201720828A (zh)	2015-11-23	2017-06-16	赫孚孟拉羅股份公司	治療性化合物及組合物以及其使用方法
WO2017108737A1 (en)	2015-12-23	2017-06-29	Chiesi Farmaceutici S.P.A.	1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
EP3394060A1 (en)	2015-12-23	2018-10-31	Chiesi Farmaceutici S.p.A.	1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
WO2017108736A1 (en)	2015-12-23	2017-06-29	Chiesi Farmaceutici S.P.A.	N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3452464B1 (en)	2016-05-05	2021-12-15	F. Hoffmann-La Roche AG	Pyrazole derivatives, compositions and therapeutic use thereof
PE20190632A1 (es)	2016-09-06	2019-04-26	Hoffmann La Roche	Compuestos 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y metodos de utilizacion de los mismos
EP3538542B1 (en)	2016-11-11	2021-08-04	Zealand Pharma A/S	Cyclic peptides multimers targeting alpha 4beta 7 integrin
MX2019007339A (es)	2016-12-29	2019-09-06	Hoffmann La Roche	Compuestos de pirazolopirimidina y metodos de uso de los mismos.
WO2018140510A1 (en)	2017-01-25	2018-08-02	Biogen Ma Inc.	Compositions and methods for treatment of stroke and other cns disorders
CN110494434B (zh)	2017-03-14	2022-05-24	豪夫迈·罗氏有限公司	吡唑并氯苯基化合物、其组合物及其使用方法
JP7274425B2 (ja)	2017-05-10	2023-05-16	ジーランドファーマアクティーゼルスカブ	α４β７インテグリンを標的とするホモデチック環状ペプチド
SG11201909735YA (en)	2017-05-22	2019-11-28	Hoffmann La Roche	Therapeutic compounds and compositions, and methods of use thereof
EP3630767A1 (en)	2017-05-22	2020-04-08	H. Hoffnabb-La Roche Ag	Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en)	2017-06-07	2019-07-30	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
WO2019139714A1 (en)	2018-01-15	2019-07-18	Genentech, Inc.	Pyrazolopyrimidine compounds as jak inhibitors
JP7189369B2 (ja)	2018-10-30	2022-12-13	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４β７インテグリンの阻害のための化合物
AU2019373242B2 (en)	2018-10-30	2023-07-13	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
HRP20250191T1 (hr)	2018-10-30	2025-04-11	Gilead Sciences, Inc.	Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti
US11174256B2 (en)	2018-10-30	2021-11-16	Gilead Sciences, Inc.	Imidazopyridine derivatives
CN113330013B (zh)	2019-01-10	2022-12-27	石药集团中奇制药技术（石家庄）有限公司	杂环化合物盐及其应用
WO2020257143A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CN114008051B (zh)	2019-06-18	2024-08-13	豪夫迈·罗氏有限公司	Jak激酶的吡唑并嘧啶砜抑制剂及其用途
WO2020257142A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
EP4013499A1 (en)	2019-08-14	2022-06-22	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1149971B (it)	1979-06-11	1986-12-10	Syntex Inc	Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en)	1985-01-23	1988-02-16	Abbott Laboratories	Functionalized peptidylaminoalcohols
US4826815A (en)	1985-05-17	1989-05-02	Abbott Laboratories	Renin inhibiting compounds
DK163689A (da)	1988-04-08	1989-10-30	Sandoz Ag	Peptidderivater
EP0506748B1 (en)	1989-12-22	1995-12-13	Commonwealth Scientific And Industrial Research Organisation	Amino acids, peptides or derivatives thereof coupled to fats
CA2043741C (en)	1990-06-07	2003-04-01	Kiyofumi Ishikawa	Endothelin antagonistic peptide derivatives
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
US5260277A (en)	1990-09-10	1993-11-09	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en)	1990-11-15	1992-05-29	Tanabe Seiyaku Co. Ltd.	Substituted urea and related cell adhesion modulation compounds
EP0519748B1 (en)	1991-06-21	1998-09-02	Merck & Co. Inc.	Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
JPH07503944A (ja)	1991-11-22	1995-04-27	イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド	Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
AU3420693A (en)	1991-12-24	1993-07-28	Fred Hutchinson Cancer Research Center	Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de)	1992-04-13	1993-10-14	Cassella Ag	Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en)	1992-07-26	1996-05-14	Yeda Res & Dev	Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
CA2153228A1 (en)	1993-01-08	1994-07-21	Shiu-Lan Ng Chiang	Peptide inhibitors of cell adhesion
US5314902A (en) *	1993-01-27	1994-05-24	Monsanto Company	Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de)	1993-03-26	1994-09-29	Cassella Ag	Neue Harnstoffderivate, ihre Herstellung und Verwendung
DK0695547T3 (da)	1993-04-09	2001-10-08	Toyama Chemical Co Ltd	Immunmodulator, celleadhæsionsinhibitor og middel til behandling og forebyggelse af autoimmunsygdomme
US5770573A (en) *	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en)	1993-12-06	1995-06-15	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
US5434188A (en)	1994-03-07	1995-07-18	Warner-Lambert Company	1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6248713B1 (en) *	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
US6239108B1 (en) *	1996-07-11	2001-05-29	Biogen, Inc.	Cell adhesion inhibitors

1995
- 1995-07-11 US US08/498,237 patent/US6248713B1/en not_active Expired - Fee Related
1996
- 1996-07-11 HU HU9802202A patent/HUP9802202A3/hu unknown
- 1996-07-11 EA EA199800119A patent/EA001594B1/ru not_active IP Right Cessation
- 1996-07-11 AU AU64894/96A patent/AU716276B2/en not_active Ceased
- 1996-07-11 TR TR1998/00028T patent/TR199800028T1/xx unknown
- 1996-07-11 CN CNB961963808A patent/CN1195778C/zh not_active Expired - Fee Related
- 1996-07-11 IL IL12278396A patent/IL122783A/xx not_active IP Right Cessation
- 1996-07-11 NZ NZ312950A patent/NZ312950A/xx unknown
- 1996-07-11 BR BR9609782A patent/BR9609782A/pt not_active Application Discontinuation
- 1996-07-11 EP EP96924444A patent/EP0842196B1/en not_active Expired - Lifetime
- 1996-07-11 WO PCT/US1996/011570 patent/WO1997003094A1/en not_active Ceased
- 1996-07-11 KR KR1019980700228A patent/KR100531586B1/ko not_active Expired - Fee Related
- 1996-07-11 PL PL96324491A patent/PL188446B1/pl not_active IP Right Cessation
- 1996-07-11 SK SK37-98A patent/SK3798A3/sk unknown
- 1996-07-11 EA EA200100103A patent/EA003737B1/ru not_active IP Right Cessation
- 1996-07-11 DE DE69637328T patent/DE69637328T2/de not_active Expired - Fee Related
- 1996-07-11 CA CA002226868A patent/CA2226868A1/en not_active Abandoned
- 1996-07-11 RO RO98-00033A patent/RO121032B1/ro unknown
- 1996-07-11 JP JP9505989A patent/JPH11511124A/ja not_active Ceased
- 1996-07-11 EE EE9700362A patent/EE03694B1/xx not_active IP Right Cessation
- 1996-07-11 EE EEP200200384A patent/EE200200384A/xx unknown
- 1996-07-11 FI FI980033A patent/FI980033A7/fi unknown
- 1996-07-11 CZ CZ0005298A patent/CZ299054B6/cs not_active IP Right Cessation
- 1996-07-12 TW TW085108493A patent/TW570927B/zh not_active IP Right Cessation
- 1996-11-07 UA UA98020687A patent/UA71888C2/uk unknown
1998
- 1998-01-08 IS IS4648A patent/IS4648A/is unknown
- 1998-01-09 NO NO980097A patent/NO980097L/no unknown
- 1998-01-12 MX MX9800348A patent/MX9800348A/es not_active IP Right Cessation
- 1998-02-10 BG BG102241A patent/BG63876B1/bg unknown
2000
- 2000-01-13 US US09/482,296 patent/US6596687B1/en not_active Expired - Fee Related
2007
- 2007-09-13 JP JP2007238556A patent/JP2008088171A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EE200200384A (et)	2002-10-15
SK3798A3 (en)	1998-07-08
US6596687B1 (en)	2003-07-22
BG63876B1 (bg)	2003-04-30
JP2008088171A (ja)	2008-04-17
EA001594B1 (ru)	2001-06-25
KR19990028926A (ko)	1999-04-15
IS4648A (is)	1998-01-08
NO980097D0 (no)	1998-01-09
UA71888C2 (en)	2005-01-17
TW570927B (en)	2004-01-11
EP0842196B1 (en)	2007-11-21
EA003737B1 (ru)	2003-08-28
JPH11511124A (ja)	1999-09-28
KR100531586B1 (ko)	2006-10-31
CZ5298A3 (cs)	1998-04-15
NZ312950A (en)	2000-01-28
EA200100103A1 (ru)	2001-06-25
EE9700362A (et)	1998-06-15
EE03694B1 (et)	2002-04-15
HUP9802202A3 (en)	1999-03-29
IL122783A0 (en)	1998-08-16
IL122783A (en)	2005-08-31
FI980033L (fi)	1998-03-05
PL188446B1 (pl)	2005-02-28
DE69637328T2 (de)	2008-10-09
US6248713B1 (en)	2001-06-19
MX9800348A (es)	1998-07-31
CZ299054B6 (cs)	2008-04-09
AU6489496A (en)	1997-02-10
HK1010888A1 (en)	1999-07-02
CA2226868A1 (en)	1997-01-30
TR199800028T1 (xx)	1998-05-21
FI980033A0 (fi)	1998-01-09
DE69637328D1 (de)	2008-01-03
HUP9802202A2 (hu)	1999-01-28
NO980097L (no)	1998-03-11
CN1193325A (zh)	1998-09-16
EA199800119A1 (ru)	1998-08-27
PL324491A1 (en)	1998-05-25
AU716276B2 (en)	2000-02-24
EP0842196A1 (en)	1998-05-20
CN1195778C (zh)	2005-04-06
BG102241A (bg)	1998-12-30
RO121032B1 (ro)	2006-11-30
WO1997003094A1 (en)	1997-01-30
FI980033A7 (fi)	1998-03-05

Publication	Publication Date	Title
BR9609782A (pt)	1999-03-09	Inibidores de adesão culular
BR9603751A (pt)	1998-06-02	Inibidores de adesão cíclica
PT858464E (pt)	2003-08-29	Inibidores de trombina
FI973087L (fi)	1997-09-22	Soluadheesion inhibiittoreita
FI962539A0 (fi)	1996-06-19	Päällystetty elintarvike
IS4771A (is)	1998-06-12	Interlevkín-1ß umbreytiensím tálmar
FI973646A7 (fi)	1997-09-09	Fraktiointilaite
PT958287E (pt)	2002-12-31	Inibidores de sulfamida-metaloprotease
ATE192525T1 (de)	2000-05-15	Plattenförmiges bauelement
PT904285E (pt)	2003-02-28	Inibidores de adesao ciclicos
DE69605683D1 (de)	2000-01-20	Lebensmitteldressing
PT863916E (pt)	2002-07-31	Tripeptidos de polifluoroalquil triptofano inibidores de trombina
PT839024E (pt)	2004-08-31	Formulacoes de monensina
BR9610514A (pt)	1999-03-30	Inibidores cicloantihelmínticos
KR970008005U (ko)	1997-03-27	수저통
KR970016153U (ko)	1997-05-23	주방용 집게
KR970000779U (ko)	1997-01-21	팬
DE69620638D1 (de)	2002-05-16	Kochgerät
KR970016247U (ko)	1997-05-23	소금찜질용구
KR960026638U (ko)	1996-08-17	젓가락
NO953210D0 (no)	1995-08-16	Kokekar
KR960033523U (ko)	1996-11-19	팬
KR960031378U (ko)	1996-10-22	수저통
KR960036197U (ko)	1996-12-16	수저통
KR960036194U (ko)	1996-12-16	수저통

Legal Events

Date	Code	Title	Description
2007-02-27	B25D	Requested change of name of applicant approved	Owner name: BIOGEN IDEC MA, INC. (US) Free format text: ALTERADO DE: BIOGEN, INC.
2007-03-13	B25D	Requested change of name of applicant approved	Owner name: BIOGEN IDEC MA INC. (US) Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.
2008-04-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2008-12-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-05-19	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI.
2009-09-22	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.